You are here

  • Home
  • Archive
  • Volume 55, Issue 10
  • Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial.

Article info

Article menu
Download PDFPDF
Research Article
Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial.

Authors

    Citation

    Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, et al
    Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial.
    Annals of the Rheumatic Diseases 1996;55:739-744.

    Publication history

    • First published October 1, 1996.
    Online issue publication 
    April 16, 2023

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.